Skip to main content

Table 1 Descriptive statistics for total cohort and two subgroups stratified by preoperative CA19–9 alteration

From: Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients

  Total cohort Subgroups P value
Normal Responder Non-responder
Number 240 49 33 158  
Gender (n)
 Male:Female 119:121 23:26 16:17 80:78 0.895
Age (year)
 Median (range) 67 (36–83) 65 (38–79) 68 (36–78) 66 (41–83) 0.881
Pre-neoadjuvant therapy CA19–9 value (U/ml)
 Median (range) 152.7 (2.0–87,100.0) 12.9 (2.0–36.4) 84.0 (39.5–1129.0) 344.8 (32.0–87,100.0) 0.151
Post-neoadjuvant therapy CA19–9 value (U/ml)
 Median (range) 57.7 (2.0–37,370.0) 8.5 (2.0–30.0) 21.0 (8.1–33.0) 134.5 (38.0–37,370.0) 0.148
% decrease of CA19–9 value (%)
 Median (range) 53.2 (−100.0–326.4) 14.7 (− 100.0–100.0) 75.6 (24.9–90.2) 54.1 (− 326.4–96.4) <.0001
Post-surgical CA19–9 value (U/ml)
 Median (range) 18.6 (2.0–3929.4) 7.0 (2.0–35.0) 9.3 (4.0–171.0) 35.1 (3.2–3929.4) 0.026
CA19–9 normalization after surgery, n(%)
 yes 164 (68) 49 (100) 29 (88) 86 (54)  
 no 76 (32) 0 (0) 4 (12) 72 (46) <.0001
Post-surgical tumor size (mm)
 Median (range) 27.0 (8.0–70.0) 24.5 (8.0–48.0) 28.0 (10.0–50.0) 28.0 (10.0–70.0) 0.026
Preoperative drainage, n (%)
 yes 152 (63) 35 (71) 17 (52) 100 (63)  
 no 88 (37) 14 (29) 16 (48) 58 (37) 0.187
NCCN resectability, n (%)
 Resectable 132 (55) 32 (65) 21 (64) 79 (50)  
 Borderline 108 (45) 17 (35) 12 (36) 79 (50) 0.096
Neoadjuvant therapy, n (%)
 Systematic chemotherapy 115 (48) 27 (55) 11 (33) 77 (49)  
 Chemoradiotherapy 125 (52) 22 (45) 22 (67) 81 (51) 0.145
Duration of neoadjuvant therapy (day)
 Median (range) 69 (13–120) 69 (22–117) 71 (44–112) 68 (13–120) 0.569
RECIST, n (%)
 Complete response 11 (5) 4 (8) 2 (6) 5 (3)  
 Partial response, 33 (14) 11 (23) 7 (21) 15 (10)  
 Stable disease 192 (80) 33 (67) 24 (73) 135 (85)  
 Progressive disease 4 (1) 1 (2) 0 (0) 3 (2) 0.096
Operation, n (%)
 Pancreaticoduodenectomy 160 (67) 33 (67) 26 (79) 101 (64)  
 Distal pancreatectomy 80 (33) 16 (33) 7 (21) 57 (36) 0.256
N classification (UICC), n (%)
 1 130 (54) 24 (49) 12 (36) 93 (59)  
 0 110 (46) 25 (51) 21 (64) 64 (41) 0.042
Residual tumor, n (%)
 R0 205 (85) 44 (90) 32 (97) 129 (82)  
 R1 35 (15) 5 (10) 1 (3) 29 (18) 0.048
Adjuvant therapy, n (%)
 yes 205 (85) 42 (86) 27 (82) 136 (86)  
 no 35 (15) 7 (14) 6 (18) 22 (14) 0.826
Completion of adjuvant therapy, n (%)
 yes 139 (67) 34 (83) 23 (85) 82 (59)  
 no 68 (33) 7 (17) 4 (15) 57 (41) 0.002
  1. NCCN National Comprehensive Cancer Network, RECIST response evaluation criteria in solid tumours